Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
letaplimab + azacitidine
- Development stage
- Unknown
- Lead developer
- Innovent Biologics
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
Letaplimab (IBI188) is a fully human monoclonal antibody that targets the CD47 antigen on tumor cells, developed by Innovent Biologics. By binding to CD47, it blocks the CD47-SIRPα signaling pathway, inhibiting the "Don't Eat Me" signal and promoting phagocytosis of tumor cells by macrophages. Azacitidine is a small molecule chemotherapeutic agent classified as a demethylation agent or antimetabolite; it works by helping bone marrow produce normal blood cells and killing abnormal cells through interference with DNA synthesis and repair. The combination of letaplimab and azacitidine is under investigation as a first-line treatment for newly diagnosed higher-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML)[2][5][6][8]. Letaplimab’s mechanism includes antibody-dependent cell cytotoxicity and T lymphocyte stimulation[8], while azacitidine acts primarily via DNA hypomethylation.
- Other names
- human anti-CD47 monoclonal antibody (IBI188)AZA
02
Targets
CD47 (Cluster of Differentiation 47)DNMT (DNA methyltransferase)
Beyond the preview
Go deeper on letaplimab + azacitidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on letaplimab + azacitidine.